Anavex Life Sciences Corp. (NASDAQ:AVXL) shares were up 13.5% during trading on Thursday . The stock traded as high as $3.58 and last traded at $3.53, with a volume of 1,250,394 shares. The stock had previously closed at $3.11.

Several research analysts recently commented on AVXL shares. FBR & Co reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Maxim Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Finally, Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Tuesday, May 31st.

The company’s 50-day moving average price is $5.56 and its 200-day moving average price is $4.84. The firm’s market cap is $122.13 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.10. On average, analysts expect that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.